Skip to main navigation
DURECT
  • ABOUT
    • ABOUT DURECT
    • MANAGEMENT
    • BOARD OF DIRECTORS
    • CORPORATE GOVERNANCE
      • BOARD COMMITTEE CHARTERS
      • CODE OF ETHICS
      • WHISTLEBLOWER POLICY
      • CORPORATE GOVERNANCE GUIDELINES
  • DUR-928
    • OVERVIEW
    • EPIGENETIC REGULATION
    • ALCOHOLIC HEPATITIS
    • NONALCOHOLIC STEATOHEPATITIS (NASH)
    • DUR-928 PUBLICATIONS
  • PIPELINE
    • OVERVIEW
    • IN DEVELOPMENT
      • DUR-928
      • POSIMIR (bupivacaine extended-release solution)
      • ORADUR® -Methylphenidate ER
      • Investigational Long-acting HIV Product
  • PLATFORM TECHNOLOGIES
    • LONG-ACTING INJECTABLES
      • SABER® PLATFORM
      • CLOUD™ PLATFORM
    • ORADUR™ ABUSE-DETERRENT TECHNOLOGY
    • ALZET® Osmotic Pumps
    • LACTEL® Absorbable Polymers
  • INVESTORS

    Investor Relations

    • Overview
    • FACTSHEETS
    • Stock Information
    • News Releases
    • Collaborations
    • Earnings Estimate
    • Analyst Coverage
    • Corporate Presentation
    • SEC Filings
    • Event Calendar
    • FAQs
    • E-mail Alerts
    • Information Request
  • NEWS
    • NEWS RELEASES
    • MEDIA KIT

INVESTORS

Investor Relations

  • Overview
  • FACTSHEETS
  • Stock Information
  • News Releases
  • Collaborations
  • Earnings Estimate
  • Analyst Coverage
  • Corporate Presentation
  • SEC Filings
  • Event Calendar
  • FAQs
  • E-mail Alerts
  • Information Request

Factsheets

Show all

  • Corporate Factsheet 179.9 KB
  • Alcoholic Hepatitis (AH) Factsheet 252.2 KB

© 2000-2020 DURECT Corporation

BUSINESS DEVELOPMENT | CAREERS | CONTACT | LEGAL NOTICE | PRIVACY POLICY